---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-033629"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:21:43.048969+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lantheus Q2 revenue up 22.5% to $394.1M, adjusted EPS $1.80; lowers FY 2024 adjusted EPS guidance to $6.60-$6.70

## Summary
- Revenue $394.1M (+22.5% YoY), driven by PYLARIFY sales $273.3M (+29.8%) and DEFINITY $78.1M (+10.7%).
- GAAP diluted EPS $0.88 (vs $1.33); adjusted diluted EPS $1.80 (vs $1.54), +16.4%.
- Acquired NAV-4694 (Alzheimer's), global rights to RM2 theranostic pair (prostate/breast), and two preclinical assets from Radiopharm Theranostics.
- FY 2024 revenue guidance reaffirmed $1.50-1.52B; adjusted EPS guidance lowered to $6.60-6.70 from $7.00-7.20 due to BD investments.
- CMS proposed OPPS rule improves separate payment for diagnostic radiopharmaceuticals like PYLARIFY in hospital outpatient setting.

## SEC filing metadata
- accession: 0001628280-24-033629
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000162828024033629/0001628280-24-033629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000162828024033629/lnth-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-033629
- JSON: https://secwatch.observer/filing/0001628280-24-033629.json
- Plain text: https://secwatch.observer/filing/0001628280-24-033629.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.